Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease
On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer's disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 percent in people ...
Dec 22, 2022
0
46